Pharmacists Provide Telemedicine in Addition to Clinic Visits to Improve Diabetes Management

Telemedicine Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02344082
• Other study ID #: IRB00051947
• Secondary ID: 1819
• Status: Completed
• Phase: N/A
• Start date: January 2015
• Est. completion date: June 2015

Study information

• Verified date: December 2018
• Source: Johns Hopkins University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This prospective study will include both an intervention and control arm. The control arm will receive face-to-face pharmacy clinic visits per standard of care. The intervention arm will receive pharmacy clinic visits plus additional telephone follow-up. Patients with a hemoglobin A1c in the last 3 months greater than 9% will be eligible. Eligible patients must have a primary care physician at Johns Hopkins Outpatient Center (JHOC) or East Baltimore Medical Center (EBMC).

Purpose: To compare the change in hemoglobin A1c over the 3 month study period in the intervention group in which patients participate in telemedicine, to a control group in which they do not

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: June 2015
• Est. primary completion date: June 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult patients with a primary care provider at JHOC or EMBC

• Patients have seen primary care provider within last 6 months

• Patients with hemoglobin A1c greater than 9%

Exclusion Criteria:

• Patients <18 years of age

• Patients with previously established care with JHH ambulatory care pharmacist

• Patients with communication barriers who do not have a caregiver

• Patients with new diagnosis of diabetes

• Patients who are pregnant or planning to become pregnant during the time of the study

• Patients followed by Endocrinology or Diabetes Center

Related Conditions & MeSH terms

• Telemedicine

Intervention

Other:
• Telemedicine
The intervention arm will receive pharmacy clinic visits plus additional telephone follow-up.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Johns Hopkins University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in hemoglobin A1c	A1c at 3 months - A1c at Baseline	3 months
Secondary	Patient adherence to office visits (# visits attended/# of visits scheduled)	# visits attended/# of visits scheduled	3 months
Secondary	Pharmacist interventions (Number of pharmacist interventions (lifestyle or medication changes) made)	Number of pharmacist interventions (lifestyle or medication changes) made	3 months
Secondary	Patient satisfaction (Based on survey results)	Based on survey results at final pharmacy clinic visit	3 months
Secondary	Telemedicine in Usual Care (Percent of patients who receive telephone call under usual care)	Percent of patients who receive telephone call under usual care	3 months
Secondary	Telemedicine Adherence (Percent of telephone encounters completed in intervention arm)	Percent of telephone encounters completed in intervention arm	3 months